{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:50:56Z","timestamp":1791154256879,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Male recipients of transplants from female (F\u2192M) hematopoietic stem cell donors represent a special group in whom donor T cells that are specific for recipient minor histocompatibility antigens encoded by Y-chromosome genes may contribute to a graft-versus-leukemia (GVL) effect and to graft-versus-host disease (GVHD). We examined the contribution of donor\/patient sex to the risk for relapse and GVHD in 3238 patients who underwent HLA-identical sibling hematopoietic stem cell transplantation (HSCT) for hematopoietic malignancies at a single institution. Compared with other sex combinations, male recipients of female transplants had the lowest risk for relapse and the greatest odds for GVHD. Remarkably, after controlling for GVHD as a time-dependent covariate, F\u2192M HSCT still exhibited a lower risk for relapse than other sex combinations, demonstrating a selective GVL effect distinct from that contributed by GVHD. A reduction in relapse after F\u2192M HSCT was observed in patients with chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), and acute lymphoblastic leukemia (ALL). Taken together, these data suggest that minor H antigens encoded or regulated by genes on the Y chromosome contribute to a selective GVL effect against myeloid and lymphoid leukemias after F\u2192M HSCT.<\/jats:p>","DOI":"10.1182\/blood-2003-07-2603","type":"journal-article","created":{"date-parts":[[2003,9,15]],"date-time":"2003-09-15T20:48:15Z","timestamp":1063658895000},"page":"347-352","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":219,"title":["Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants"],"prefix":"10.1182","volume":"103","author":[{"given":"Sophia S. B.","family":"Randolph","sequence":"first","affiliation":[{"name":"From the Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA; and the Department of Medicine, University of Washington School of Medicine, Seattle."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore A.","family":"Gooley","sequence":"additional","affiliation":[{"name":"From the Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA; and the Department of Medicine, University of Washington School of Medicine, Seattle."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edus H.","family":"Warren","sequence":"additional","affiliation":[{"name":"From the Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA; and the Department of Medicine, University of Washington School of Medicine, Seattle."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"From the Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA; and the Department of Medicine, University of Washington School of Medicine, Seattle."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley R.","family":"Riddell","sequence":"additional","affiliation":[{"name":"From the Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA; and the Department of Medicine, University of Washington School of Medicine, Seattle."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222261222700_REF1","doi-asserted-by":"crossref","unstructured":"Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75: 555-562.","DOI":"10.1182\/blood.V75.3.555.555"},{"key":"2020021222261222700_REF2","doi-asserted-by":"crossref","unstructured":"Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300: 1068-1073.","DOI":"10.1056\/NEJM197905103001902"},{"key":"2020021222261222700_REF3","doi-asserted-by":"crossref","unstructured":"Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304: 1529-1533.","DOI":"10.1056\/NEJM198106183042507"},{"key":"2020021222261222700_REF4","doi-asserted-by":"crossref","unstructured":"Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80: 1838-1845.","DOI":"10.1182\/blood.V80.7.1838.1838"},{"key":"2020021222261222700_REF5","doi-asserted-by":"crossref","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versustumor effects. Blood. 2001;97: 3390-3400.","DOI":"10.1182\/blood.V97.11.3390"},{"key":"2020021222261222700_REF6","doi-asserted-by":"crossref","unstructured":"Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86: 2041-2050.","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041"},{"key":"2020021222261222700_REF7","doi-asserted-by":"crossref","unstructured":"Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15: 433-444.","DOI":"10.1200\/JCO.1997.15.2.433"},{"key":"2020021222261222700_REF8","doi-asserted-by":"crossref","unstructured":"Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101: 1620-1629.","DOI":"10.1182\/blood-2002-05-1340"},{"key":"2020021222261222700_REF9","doi-asserted-by":"crossref","unstructured":"Feinstein LC, Sandmaier BM, Hegenbart U, et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol. 2003;120: 281-288.","DOI":"10.1046\/j.1365-2141.2003.04057.x"},{"key":"2020021222261222700_REF10","doi-asserted-by":"crossref","unstructured":"Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16: 2817-2824.","DOI":"10.1200\/JCO.1998.16.8.2817"},{"key":"2020021222261222700_REF11","doi-asserted-by":"crossref","unstructured":"Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102: 756-762.","DOI":"10.1182\/blood-2002-08-2628"},{"key":"2020021222261222700_REF12","doi-asserted-by":"crossref","unstructured":"Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med. 2001;7: 789-794.","DOI":"10.1038\/89907"},{"key":"2020021222261222700_REF13","unstructured":"Truitt RL, Atasoylu AA. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant. 1991;8: 51-58."},{"key":"2020021222261222700_REF14","doi-asserted-by":"crossref","unstructured":"Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1\u2013 or HA-2\u2013specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A. 2003;100: 2742-2747.","DOI":"10.1073\/pnas.0530192100"},{"key":"2020021222261222700_REF15","doi-asserted-by":"crossref","unstructured":"Faber LM, van der Hoeven J, Goulmy E, et al. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest. 1995;96: 877-883.","DOI":"10.1172\/JCI118134"},{"key":"2020021222261222700_REF16","doi-asserted-by":"crossref","unstructured":"Warren EH, Gavin M, Greenberg PD, Riddell SR. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol. 1998;5: 429-433.","DOI":"10.1097\/00062752-199811000-00013"},{"key":"2020021222261222700_REF17","doi-asserted-by":"crossref","unstructured":"Mutis T, Goulmy E. Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies. Semin Hematol. 2002;39: 23-31.","DOI":"10.1053\/shem.2002.29248"},{"key":"2020021222261222700_REF18","doi-asserted-by":"crossref","unstructured":"Wang W, Meadows LR, den Haan JM, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science. 1995;269: 1588-1590.","DOI":"10.1126\/science.7667640"},{"key":"2020021222261222700_REF19","doi-asserted-by":"crossref","unstructured":"Meadows L, Wang W, den Haan JM, et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity. 1997;6: 273-281.","DOI":"10.1016\/S1074-7613(00)80330-1"},{"key":"2020021222261222700_REF20","doi-asserted-by":"crossref","unstructured":"Warren EH, Gavin MA, Simpson E, et al. The human UTY gene encodes a novel HLA-B8\u2013restricted H-Y antigen. J Immunol. 2000;164: 2807-2814.","DOI":"10.4049\/jimmunol.164.5.2807"},{"key":"2020021222261222700_REF21","doi-asserted-by":"crossref","unstructured":"Vogt MH, de Paus RA, Voogt PJ, Willemze R, Falkenburg JH. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood. 2000;95: 1100-1105.","DOI":"10.1182\/blood.V95.3.1100.003k42_1100_1105"},{"key":"2020021222261222700_REF22","doi-asserted-by":"crossref","unstructured":"Vogt MH, van den Muijsenberg JW, Goulmy E, et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood. 2002;99: 3027-3032.","DOI":"10.1182\/blood.V99.8.3027"},{"key":"2020021222261222700_REF23","doi-asserted-by":"crossref","unstructured":"Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med. 2002;8: 410-414.","DOI":"10.1038\/nm0402-410"},{"key":"2020021222261222700_REF24","doi-asserted-by":"crossref","unstructured":"Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med. 1999;5: 839-842.","DOI":"10.1038\/10563"},{"key":"2020021222261222700_REF25","doi-asserted-by":"crossref","unstructured":"Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8+ minor histocompatability antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A. 1999;96: 8639-8644.","DOI":"10.1073\/pnas.96.15.8639"},{"key":"2020021222261222700_REF26","doi-asserted-by":"crossref","unstructured":"Flowers ME, Pepe MS, Longton G, et al. Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. Br J Haematol. 1990;74: 492-496.","DOI":"10.1111\/j.1365-2141.1990.tb06340.x"},{"key":"2020021222261222700_REF27","doi-asserted-by":"crossref","unstructured":"Atkinson K, Farrell C, Chapman G, Downs K, Penny R, Biggs J. Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. Br J Haematol. 1986;63: 231-239.","DOI":"10.1111\/j.1365-2141.1986.tb05545.x"},{"key":"2020021222261222700_REF28","doi-asserted-by":"crossref","unstructured":"Gratwohl A, Hermans J, Niederwieser D, van Biezen A, van Houwelingen HC, Apperley J. Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J. 2001;2: 363-370.","DOI":"10.1038\/sj.thj.6200117"},{"key":"2020021222261222700_REF29","unstructured":"Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15: 825-828."},{"key":"2020021222261222700_REF30","doi-asserted-by":"crossref","unstructured":"Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57: 267-276.","DOI":"10.1182\/blood.V57.2.267.267"},{"key":"2020021222261222700_REF31","doi-asserted-by":"crossref","unstructured":"Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73: 1720-1728.","DOI":"10.1182\/blood.V73.6.1720.1720"},{"key":"2020021222261222700_REF32","doi-asserted-by":"crossref","unstructured":"Porter DL, Antin JH. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med. 1999;50: 369-386.","DOI":"10.1146\/annurev.med.50.1.369"},{"key":"2020021222261222700_REF33","doi-asserted-by":"crossref","unstructured":"Korngold R, Leighton C, Manser T. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation. 1994;58: 278-287.","DOI":"10.1097\/00007890-199408000-00004"},{"key":"2020021222261222700_REF34","doi-asserted-by":"crossref","unstructured":"Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med. 2003;197: 1279-1289.","DOI":"10.1084\/jem.20030044"},{"key":"2020021222261222700_REF35","doi-asserted-by":"crossref","unstructured":"Gratwohl A, Brand R, Apperley J, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood. 2002;100: 3877-3886.","DOI":"10.1182\/blood.V100.12.3877"},{"key":"2020021222261222700_REF36","doi-asserted-by":"crossref","unstructured":"Ringden O, Labopin M, Gorin NC, et al. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br J Haematol. 2000;111: 1130-1137.","DOI":"10.1046\/j.1365-2141.2000.02493.x"},{"key":"2020021222261222700_REF37","doi-asserted-by":"crossref","unstructured":"Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood. 2003;102: 31-35.","DOI":"10.1182\/blood-2002-08-2619"},{"key":"2020021222261222700_REF38","unstructured":"Randolph SB, Warren EH, Riddell SR. Identification of novel minor histocompatibility antigens encoded by the Y chromosome gene, UTY [abstract]. Blood. 2002;100: 615a."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/1\/347\/1694206\/zh800104000347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/1\/347\/1694206\/zh800104000347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T22:26:25Z","timestamp":1581546385000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/1\/347\/17596\/Female-donors-contribute-to-a-selective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-07-2603","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}